Document is current

Any future updates will be listed below

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-016-3979-5

Published Online: 2016-09-21

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark